Biomarkers for determining the prognosis in chronic myelogenous leukemia
Open Access
- 19 July 2013
- journal article
- review article
- Published by Springer Science and Business Media LLC in Journal of Hematology & Oncology
- Vol. 6 (1), 54-9
- https://doi.org/10.1186/1756-8722-6-54
Abstract
The introduction of BCR-ABL1 tyrosine kinase inhibitors (TKIs) for treatment of chronic myelogenous leukemia in chronic phase (CML-CP) has revolutionized therapy, altering the outcome from one of shortened life expectancy to long-term survival. With over 10 years of long-term treatment with imatinib and several years of experience with the next generation of TKIs, including nilotinib, dasatinib, bosutinib, and ponatinib, it is becoming clear that many clinical parameters have great impact on the prognosis of patients with CML. Emerging novel gene expression profiling and molecular techniques also provide new insights into CML pathogenesis and have identified potential prognostic markers and therapeutic targets. This review presents the supporting data and discusses how certain clinical characteristics at diagnosis, the depth of early response, the presence of certain kinase domain mutations, and additional molecular changes serve as prognostic factors that may guide individualized treatment decisions for patients with CML-CP.Keywords
This publication has 49 references indexed in Scilit:
- EUTOS score is not predictive for survival and outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors: a single institution experienceBlood, 2012
- Predicting relapse prior to transplantation in chronic myeloid leukemia by integrating expert knowledge and expression dataBioinformatics, 2012
- Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS scoreBlood, 2011
- Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS)Blood, 2010
- A gene expression signature of CD34+ cells to predict major cytogenetic response in chronic-phase chronic myeloid leukemia patients treated with imatinibBlood, 2010
- Non random distribution of genomic features in breakpoint regions involved in chronic myeloid leukemia cases with variant t(9;22) or additional chromosomal rearrangementsMolecular Cancer, 2010
- The derivation of diagnostic markers of chronic myeloid leukemia progression from microarray dataBlood, 2009
- Chronic myeloid leukemia patients with the e13a2 BCR-ABL fusion transcript have inferior responses to imatinib compared to patients with the e14a2 transcriptHaematologica, 2009
- Complex Variant t(9;22) Chromosome Translocations in Five Cases of Chronic Myeloid LeukemiaAdvances in Hematology, 2009
- On the genesis and prognosis of variant translocations in chronic myeloid leukemiaCancer Genetics and Cytogenetics, 2007